Damora Therapeutics, Inc. (DMRA)

NASDAQ: DMRA · USD

$21.7

-0.31 (-1.4%)· Recorded snapshot

Market cap	1.3B
Net income (ttm)	-241.3M
EPS (ttm)	-$9.88
Shares out	61.7M
Volume	267,600
Beta	1.44

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -241.3M
EPS (ttm): -$9.88
Market cap: 1.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-99.7

P25 n/aP50 n/aP75 n/a

ROIC-22.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DMRA indicators

Market & fundamental data

Available fields

176

Groups with data

Currency

USD

Showing 176 of 176 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001800315
Company name	Damora Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	G2646Y104
Earnings date	2026-11-09
Earnings time	amc
Employees	7
Employees change	2
Employees growth	40%
Enterprise value	$796.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2011
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-10-29
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG2646Y1044
Last 10-K release date	2026-03-19
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2024-08-30
Last stock split type	Reverse
Market cap	$1.3B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	No
Price	$21.65
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	DMRA
U.S. state	Massachusetts
Website	https://www.damoratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-45.62%
FCF / EV yield	-5.54%
FCF yield	-3.31%
P/B ratio	3.51x
Price / tangible book value	3.48x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-34.5M
ROA	-21.61%
ROA (5Y)	-31.38%
ROCE	-18.67%
ROE	-99.74%
ROE (5Y)	-87.97%
ROIC	-22.85%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	14
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$22,000
EBIT	$-96.3M
EBITDA	$-96.3M
EPS	$-9.88
FCF per share	$-0.72
Financing cash flow	$592.3M
Free cash flow	$-44.5M
Free cash flow minus SBC	$-54.5M
Income taxes	$341,000
Investing cash flow	$-17.4M
Net cash flow	$530.3M
Net income	$-241.3M
Operating cash flow minus SBC	$-54.5M
Operating income	$-96.3M
Stock-based compensation	$9.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$6.25
Debt / equity	0
Long-term assets	$48,000
Long-term liabilities	$27,000
Net cash (debt)	$540.5M
Net cash / market cap	40.2%
Net cash growth	5,232.63%
Net debt / equity	-1.05
Piotroski F-Score	2
Shareholders' equity	$516.1M
Tangible book value	$386.1M
Tangible book value per share	$6.25
Total assets	$543.6M
Total cash	$540.5M
Total debt	$0
Total liabilities	$27.6M
WACC	12.14%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$543.6M
Current liabilities	$27.6M
Current ratio	19.73
Net working capital	$-24.5M
Quick ratio	19.65
Working capital	$516M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1,814.32%
Dividend yield	0%
Shareholder yield	-1,814.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$25.45
1D price change	-1.41%
1M price change	4.7%
1M total return	4.7%
1W price change	0.46%
1W total return	0.46%
1Y price change	194.49%
1Y return CAGR	194.7%
1Y total return	194.49%
20-day SMA	$20.30
200-day SMA	$25.68
3M price change	-26.53%
3M total return	-26.53%
3Y price change	62.05%
3Y return CAGR	17.46%
3Y total return	62.05%
50-day SMA	$23.92
50-day SMA vs 200-day SMA	50under200
52-week high	$38.33
52-week high date	2025-12-26
52-week low	$4.95
52-week low date	2025-11-07
5Y price change	-73.86%
5Y return CAGR	-23.54%
5Y total return	-73.86%
6M price change	-15.18%
6M total return	-15.18%
All-time high	$449.75
All-time high date	2020-11-23
All-time low	$2.01
All-time low date	2025-04-09
Average true range (ATR)	$1.53
Average volume	457.6K
Beta (1Y)	1.15
Beta (2Y)	0.07
Beta (5Y)	1.44
Change from 52-week high	-43.51%
Change from 52-week low	337.37%
Change from all-time high	-95.19%
Change from all-time low	976.12%
Change from open	-2.65%
Day's gap	1.28%
Dollar volume	$5.8M
High price	$22.24
Low price	$21.59
Monthly RSI	47.24
Open price	$22.24
Position in 52-week range	9.23%
Previous close	$21.96
Price vs 150-day SMA	-15.02%
Price vs 20-day SMA	6.53%
Price vs 200-day SMA	-15.77%
Price vs 50-day SMA	-9.56%
Relative volume	0.59
Return from IPO open	-94.19%
RSI	50.91
Sharpe ratio	1.05
Sharpe ratio (3Y)	0.63
Sharpe ratio (5Y)	0.42
Sortino ratio	4.37
Sortino ratio (3Y)	2.68
Sortino ratio (5Y)	1.42
Volume	267.6K
Weekly RSI	44.96
YTD price change	-6%
YTD total return	-6%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	40.9M
Float percentage	66.23%
Shares change (QoQ)	80.91%
Shares change (YoY)	1,814.32%
Shares held by insiders	1.07%
Shares held by institutions	79.7%
Shares outstanding	61.7M
Short % of float	11.58%
Short % of shares	7.67%
Short ratio	6.1 days

Deeper analysis on DMRA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DMRA report

Is a complete DMRA research report available?

No complete published report is available for Damora Therapeutics, Inc. (DMRA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Damora Therapeutics, Inc. (DMRA)

Price

Financial snapshot

Fair-value bridge

Latest news · DMRA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DMRA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DMRA

Frequently asked questions